A Phase 2 interventional study of Trevogrumab-Part A and Trevogrumab-Part B and Part C in Obesity, sponsored by Regeneron Pharmaceuticals. Completed at 60 sites in 2 countries. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is researching experimental drugs called trevogrumab and garetosmab (called "study drugs") in combination with another drug, semaglutide (Wegovy®). This study will be done in 3 parts, Part A, Part B, and Part C where different study drugs will be tested.
Part A of the study is focused on healthy participants. Part B and C of the study is focused on participants with obesity.
The aim of Part A of the study is to see how safe and tolerable the study drug is in healthy participants. The aim of Part B and Part C of the study is to see how safe and effective the study drug is when combined with Wegovy.
Parts A, B, and C of the study are looking at several other research questions, including:
Part A Healthy Volunteers
Part B and Part C (starts after treatment for Part A has completed) Participants with Obesity
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 1,005 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria
Part A
≥18 and ≤32 kg/m2, at the screening visit
Part B and Part C
Key Exclusion Criteria
Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A Randomized 1:1
Drug: Matching Placebo-Part A
Part A Randomized 1:1
Drug: Trevogrumab-Part A
Part B Semaglutide (sema) and subcutaneous (SC) placebo and intravenous (IV) placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab · Drug: Matching Placebo-Garetosmab
Part B Sema and SC placebo and IV placebo followed by high dose trevogrumab (trevo) Randomized 1:1:1:1:1:1:1:1
Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab · Drug: Matching Placebo-Garetosmab
Part B Sema, moderate-high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab · Drug: Matching Placebo-Garetosmab
Part B Sema, moderate-high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Garetosmab
Part B Sema, high dose trevo, and IV placebo followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab · Drug: Matching Placebo-Garetosmab
Part B Sema, high dose trevo, and IV placebo followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Garetosmab
Part B Sema, high dose trevo, and garetosmab (gareto) followed by SC placebo Randomized 1:1:1:1:1:1:1:1
Drug: Trevogrumab-Part B and Part C · Drug: Garetosmab · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab
Part B Sema, high dose trevo, and gareto followed by high dose trevo Randomized 1:1:1:1:1:1:1:1
Drug: Trevogrumab-Part B and Part C · Drug: Garetosmab · Drug: Semaglutide
Part C Sema and SC placebo Randomized 1:2:2
Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab
Part C Sema and SC low dose trevo Randomized 1:2:2
Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide · Drug: Matching Placebo-Trevogrumab
Part C Sema and SC moderate dose trevo Randomized 1:2:2
Drug: Trevogrumab-Part B and Part C · Drug: Semaglutide
Administered IV or SC in Part A
Also known as: REGN1033, GDF8
Drug page: Trevogrumab
Administered SC in Part B, Part C
Also known as: REGN1033, GDF8
Administered IV in Part B
Also known as: REGN2477, Activin A
Administered SC in Part B and Part C
Also known as: Wegovy®
Administered IV or SC in Part A
Administered SC in Part B and Part C
Administered IV in Part B
Incidence of treatment-emergent adverse events (TEAEs)
Part A
Time frame: Baseline to week 7
Severity of TEAEs
Part A
Time frame: Baseline to week 7
Percent change in total fat mass
Part B
Time frame: Baseline to week 26
Percent change in total lean mass
Part B
Time frame: Baseline to week 26
Percent change in body weight
Part B
Time frame: Baseline to week 26
Percent change in total fat mass
Part C
Time frame: Baseline to week 52
Percent change in total lean mass
Part C
Time frame: Baseline to week 52
Percent change in body weight
Part C
Time frame: Baseline to week 52
Concentrations of trevogrumab in serum over time
Part A, Part B, and Part C
Time frame: Up to 75 weeks
Percent change in total fat mass
Part B
Time frame: Baseline to week 52
Percent change in total lean mass
Part B
Time frame: Baseline to week 52
Percent change in body weight
Part B
Time frame: Baseline to week 52
Change in waist circumference (cm)
Part B and Part C
Time frame: Baseline to week 26
Change in waist circumference (cm)
Part C
Time frame: Baseline to week 52
Percent change in fasting serum triglycerides
Part B
Time frame: Baseline to week 26
Percent change in total cholesterol
Part B
Time frame: Baseline to week 26
Percent change in Apolipoprotein B (Apo B)
Part B
Time frame: Baseline to week 26
Percent change in Low-Density Lipoprotein Cholesterol (LDL-C)
Part B
Time frame: Baseline to week 26
Concentrations of garetosmab in serum over time
Part B
Time frame: Up to 75 weeks
Incidence of anti-drug antibodies (ADA) to trevogrumab after repeated doses over time
Part B and Part C
Time frame: Up to 75 weeks
Magnitude of ADAs to trevogrumab over time
Part B and Part C
Time frame: Up to 75 weeks
Incidence of ADAs to garetosmab after repeated doses over time
Part B
Time frame: Up to 75 weeks
Magnitude of ADAs to garetosmab over time
Part B
Time frame: Up to 75 weeks
Incidence of TEAEs
Part B and Part C
Time frame: Up to 75 weeks
Severity of TEAEs
Part B and Part C
Time frame: Up to 75 weeks
Percent change in total fat mass
Part C
Time frame: Baseline to week 26
Percent change in total lean mass
Part C
Time frame: Baseline to week 26
Percent change in body weight
Part C
Time frame: Baseline to week 26
Concentration of total Growth Differentiation Factor (GDF) 8 in serum over time
Part C
Time frame: Up to 75 weeks
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy.
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Mar 2024 to primary completion in Jun 2026, 27 months.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 27 months is above that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Trevogrumab · Garetosmab